Angiogenesis inhibitors in gastric and gastroesophageal junction cancer

Giandomenico Roviello; Roberto Petrioli; Luigi Marano; Karol Polom; Daniele Marrelli; Armando Perrella; Franco Roviello

doi:10.1007/s10120-015-0537-5

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer

Gastric Cancer. 2016 Jan;19(1):31-41. doi: 10.1007/s10120-015-0537-5. Epub 2015 Sep 2.

Authors

Giandomenico Roviello¹, Roberto Petrioli², Luigi Marano³, Karol Polom³, Daniele Marrelli⁴, Armando Perrella², Franco Roviello³

Affiliations

¹ Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy. giandomenicoroviello@hotmail.it.
² Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
³ Unit of General and Minimally Invasive Surgery, Department of Medical, Surgical and Neuroscience, University of Siena, Viale Bracci 11, Siena, 53100, Italy.
⁴ Section of Advanced Surgical Oncology, Department of Medical, Surgical and Neurosciences, University of Siena, Viale Bracci 11, Siena, 53100, Italy.

PMID: 26329368
DOI: 10.1007/s10120-015-0537-5

Abstract

Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.

Keywords: Bevacizumab; Gastric cancer; Ramucirumab; VEGF.

Publication types

Review

MeSH terms

Adenocarcinoma / drug therapy
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab / therapeutic use
Biomarkers, Tumor / analysis
Esophageal Neoplasms / drug therapy
Esophagogastric Junction / pathology
Humans
Molecular Targeted Therapy / methods
Ramucirumab
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / pathology
TOR Serine-Threonine Kinases / antagonists & inhibitors
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biomarkers, Tumor
VEGFA protein, human
Vascular Endothelial Growth Factor A
Bevacizumab
MTOR protein, human
TOR Serine-Threonine Kinases

Supplementary concepts

Adenocarcinoma Of Esophagus